Quick Answer
ULTRALIFE CORP reported R&D Expense of $10.40 million for fiscal year 2025.
ULTRALIFE CORP R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $10.40M | +25.8% |
| 2024 | $8.27M | +9.8% |
| 2023 | $7.53M | +6.4% |
| 2022 | $7.08M | +3.7% |
| 2021 | $6.83M | +14.8% |
| 2020 | $5.95M | -12.6% |
| 2019 | $6.80M | +51.0% |
| 2018 | $4.51M | -4.8% |
| 2017 | $4.74M | -20.3% |
| 2016 | $5.95M | +6.1% |
| 2015 | $5.60M | +5.1% |
| 2014 | $5.33M | -9.0% |
| 2013 | $5.86M | -18.8% |
| 2012 | $7.22M | -16.0% |
| 2011 | $8.59M | -1.9% |
| 2010 | $8.76M | -7.4% |
| 2009 | $9.45M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.85M | +35.9% | +23.2% |
| June 30, 2025 | $2.32M | +16.1% | -3.6% |
| March 31, 2025 | $2.40M | +36.9% | +14.4% |
| September 30, 2024 | $2.10M | +12.4% | +5.2% |
| June 30, 2024 | $2.00M | +12.3% | +13.7% |
| March 31, 2024 | $1.76M | -13.6% | -6.0% |
| September 30, 2023 | $1.87M | -1.4% | +5.1% |
| June 30, 2023 | $1.78M | +6.3% | -12.5% |
- ULTRALIFE CORP showed an increase of +25.8% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, ULTRALIFE CORP’s r&d expense has grown by 10.0% (from $9.45 million to $10.40 million).
- The most recent figure is from ULTRALIFE CORP’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: